Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  HOOKIPA Pharma Inc.    HOOK

HOOKIPA PHARMA INC.

(HOOK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/23/2021 02/24/2021 02/25/2021 02/26/2021 03/01/2021 Date
11.48(c) 11.76(c) 11.65(c) 11.84(c) 11.95(c) Last
117 438 99 825 84 730 142 625 176 711 Volume
-3.04% +2.44% -0.94% +1.63% +0.93% Change
More quotes
Financials (USD)
Sales 2020 18,7 M - -
Net income 2020 -48,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -6,34x
Yield 2020 -
Sales 2021 16,2 M - -
Net income 2021 -66,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,94x
Yield 2021 -
Capitalization 399 M 399 M -
Capi. / Sales 2020 21,4x
Capi. / Sales 2021 24,6x
Nbr of Employees 95
Free-Float 72,4%
More Financials
Company
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation... 
Sector
Pharmaceuticals
Calendar
03/25Earnings Release
More about the company
Notations Surperformance© of HOOKIPA Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
All news about HOOKIPA PHARMA INC.
02/16HOOKIPA PHARMA  : to Participate in Upcoming SVB Leerink Global Healthcare Confe..
AQ
2020HOOKIPA PHARMA  : Announces Closing of Public Offering of $80.9 Million of Commo..
AQ
2020HOOKIPA PHARMA  : Pockets Extra $6 Million After Underwriters Exercise Over-Allo..
MT
2020HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Commo..
GL
2020HOOKIPA PHARMA INC.  : Amendments to Articles of Inc. or Bylaws; Change in Fisca..
AQ
2020HOOKIPA PHARMA INC.  : Entry into a Material Definitive Agreement, Other Events,..
AQ
2020HOOKIPA PHARMA  : Prices $75 Million Public Offering
MT
2020HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Prefe..
GL
2020HOOKIPA PHARMA  : Plans Underwritten Offering of Shares, Convertible Preferred
MT
2020HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferr..
GL
2020HOOKIPA PHARMA  : Releases Positive Interim Data From Study of Potential HPV+ Ca..
MT
2020HOOKIPA PHARMA INC.  : Regulation FD Disclosure, Other Events, Financial Stateme..
AQ
2020HOOKIPA PHARMA  : Interim Phase 1 Monotherapy Data of HB-201 for the Treatment o..
AQ
2020HOOKIPA PHARMA  : RBC Adjusts HOOKIPA Pharma's Price Target to $22 From $18, Mai..
MT
2020HOOKIPA PHARMA  : Reports Positive Phase 2 Interim Data for Positive Phase 2 Int..
MT
More news
News in other languages on HOOKIPA PHARMA INC.

- No features available -

More news
Analyst Recommendations on HOOKIPA PHARMA INC.
More recommendations
Chart HOOKIPA PHARMA INC.
Duration : Period :
HOOKIPA Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOOKIPA PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 22,00 $
Last Close Price 11,95 $
Spread / Highest target 134%
Spread / Average Target 84,1%
Spread / Lowest Target 33,9%
EPS Revisions
Managers and Directors
NameTitle
Jörn Aldag Chief Executive Officer & Director
Reinhard Kandera Chief Financial Officer & Director
Jan G. J. van de Winkel Chairman
Igor Matushansky Chief Medical Officer & Global Head-Research
Roman Necina Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
HOOKIPA PHARMA INC.7.75%399
JOHNSON & JOHNSON1.23%418 801
ROCHE HOLDING AG-2.83%281 718
NOVARTIS AG-4.73%196 893
ABBVIE INC.1.18%191 439
PFIZER INC.-9.02%187 968